Rhythm Pharmaceuticals (MEX:RYTM) Tariff Resilience Score: 7/10 (As of Jul. 02, 2026)


MEX:RYTM Rhythm Pharmaceuticals Inc MEX:RYTM
56 GF Score
Price MXN1,866.76
GF Value MXN1,874.87
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Tariff Resilience Score?

Rhythm Pharmaceuticals MEX:RYTM 56 Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus rates MEX:RYTM with a GF Score™ of 56/100 and a GF Value™ of MXN1,874.87. The stock has 3 warning signs investors should review. Among 1,374 Biotechnology companies, Rhythm Pharmaceuticals ranks better than 90.39% on this metric.

Rhythm Pharmaceuticals has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Rhythm Pharmaceuticals has Pharmaceuticals with limited direct tariff exposure. Previous tariffs had minimal impact. Strong pricing power and alternative suppliers enhance resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Rhythm Pharmaceuticals might have Highly Resilient.

Rhythm Pharmaceuticals  (MEX:RYTM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Rhythm Pharmaceuticals Tariff Resilience Score Related Terms

MEX:RYTM vs MIRM, SYRE, PTGX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rhythm Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Tariff Resilience Score falls into.


MEX:RYTM
56GF Score
Rhythm Pharmaceuticals Inc MEX:RYTM
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Rhythm Pharmaceuticals (MEX:RYTM) has a Tariff Resilience Score of 7 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Rhythm Pharmaceuticals ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Rhythm Pharmaceuticals' Tariff Resilience Score too high?
Rhythm Pharmaceuticals' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Rhythm Pharmaceuticals' value of 7 is 75% above this industry median. Based on the distribution chart, Rhythm Pharmaceuticals ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Tariff Resilience Score compare to MIRM and SYRE?
According to the Biotechnology industry distribution chart, Rhythm Pharmaceuticals ranks #132 out of 1374 companies for Tariff Resilience Score. This places Rhythm Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Rhythm Pharmaceuticals' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Pharmaceuticals's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Pharmaceuticals's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Tariff Resilience Score of 7. The stock's GF Value™ is MXN1,874.87, compared to a current price of MXN1,866.76 — trading 0.4% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of MXN1,866.76 is trading 0.4% below its estimated GF Value™ of MXN1,874.87.

Key valuation signals for MEX:RYTM:

  • Tariff Resilience Score: 7
  • GF Value™: MXN1,874.87 vs. price of MXN1,866.76 (0.4% below fair value)
  • GF Score™: 56/100 with 3 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1374)

No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score

Get the complete analysis for MEX:RYTM

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,866.76
Price
MXN1,874.87
GF Value